Bioprocessing White Papers

  1. Accelerating An Innovative High Potency Oncology Therapy To Market 5/13/2026

    Learn how disciplined containment, proactive risk management, and collaboration accelerate complex oncology programs under tight timelines while protecting quality, safety, and global launch readiness.

  2. Unlocking Durable Allogeneic Cell Therapy 5/13/2026

    Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases.

  3. Accelerating ADC Analytical Method Development Through Platform Innovation 5/11/2026

    Leverage a platform-based analytical development strategy to accelerate ADC IND readiness through early CQA identification, reduced development risk, and streamlined progression from development to patients.

  4. (Cross-) Contamination Control Through Effective Equipment Cleaning 5/6/2026

    Discover science-driven cleaning strategies that reduce cross-contamination, enable safe multiproduct manufacturing, and support faster, flexible GMP changeovers.

  5. The Importance Of Polymorph Screenings 5/6/2026

    Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.

  6. Deciphering Nanoparticle Properties With AF4 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

  7. Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

  8. Drug Substance For Early Clinical Phase Initiation 5/6/2026

    Explore how proactive nitrosamine impurity risk assessment protects early clinical drug supply, minimizes development delays, and enables confident progression to first‑in‑human studies.

  9. Accelerating Drug Development: Solid State Chemistry And Strategic Outsourcing 5/6/2026

    Discover how phase‑appropriate solid‑state chemistry and strategic outsourcing reduce risk, speed development timelines, and enable confident solid‑form selection for complex small‑molecule programs.

  10. Advancing Nanomedicine Production With Flow Manufacturing 5/6/2026

    Learn how flow manufacturing enables scalable, reproducible nanomedicine production with tighter control, consistent particle quality, and smooth lab-to-commercial scale‑up.